The purpose of this study is to compare the genes of African American children and adults who have inflammatory bowel disease (IBD) with the genes of those who do not have IBD. Genes are pieces of hereditary material found in human cells. How an individual's genes cause intestinal inflammation in IBD is still being tested and not much is known about the association between genes and IBD in individuals with African ancestry. We hope to understand which genes cause IBD and if certain genes can help doctors personalize treatment for patients with IBD. For more information please contact IBDResearch@email.chop.edu.

The purpose of this research study is to collect different types of samples (such as stool, swabs, urine) to form a biorepository. This repository will provide valuable samples from people with and without IBD so that investigators can learn more about the cause of IBD, and different therapies that could be used to treat it. These samples will be used for future gastrointestinal research. Because technology and scientific understanding may advance quickly, it is not yet known what specific studies the samples may be used for.

CAPTURE Inflammatory Bowel Disease (IBD) is a multi-center, longitudinal study designed with the goal of advancing precision medicine in pediatric IBD. Participants in CAPTURE IBD will continue to receive their usual care at the Children's Hospital of Philadelphia. The study team will ask participants to give blood, stool, and tissue samples at the same time as scheduled IBD clinical visits, endoscopy, or bowel surgery visits. Additionally, participants will be asked to complete electronic surveys at scheduled clinic visits, including any scheduled endoscopy or bowel surgery visits. The study will use the biospecimens and health data as a research resource that can help scientists to answer questions like:

• Can we help guide the selection of the most effective IBD therapies for pediatric and young adult populations?
• Can we help identify new treatments for pediatric patients who are not responding to current available therapies?
• Can we advance our understanding of who are the best candidates for surgery in pediatric Crohn's disease and the best treatment approaches after surgery?

CAPTURE IBD will enroll 3,000 patients, ages 4-21 years old, who have an established or suspected diagnosis of IBD at 12 sites across the United States.

Children's Hospital of Philadelphia (CHOP) is inviting healthy individuals ages 0-21 to become part of a unique opportunity to help other kids heal: the CHOP Pediatric Fecal Microbiota Transplant (FMT) Stool Bank. This unique program is the first of its kind in the United States and offers screened stool donations from healthy children that may be used to provide life-changing treatment for children suffering from serious gut infections like recurrent C. difficile - an illness that can cause significant symptoms and complications. Contributing to this program could make a direct difference in providing safe and effective treatment options for serious gut infections in children.

The purpose of this study is to assess the efficacy, safety, and how the body interacts with an investigational drug in pediatric patients with Crohn's disease who have not had success with other medications. After study participants are screened, if eligible, they will receive the study drug. The study drug in this study is called Upadacitinib. While Upadacitinib is FDA-approved for use in adults with Crohn's Disease, it is investigational for children with Crohn's Disease.

The purpose of this investigation is to evaluate the impact of non-persistent and persistent chemical exposures on autoimmunity, gene expression and the microbiome in children with and without Crohns disease. If these chemical exposures are associated with differences in the epigenome and microbiome that are known to predispose for Crohns disease, the proposed research could further support changes in dietary behaviors to limit exposure, and efforts to regulate manufacturing processes that unintentionally and intentionally add these chemicals to food.

The University of Pennsylvania, in collaboration with CHOP, is conducting a study to find out more about how behaviors (eating, physical activity, sleep) and genes affect growth and development in children. Participants will include children, ages 5 to 7, and their mothers.

Families will be asked to participate in a screening visit and 3 study visits over 1 year. Child participants will be asked to:

• Eat dinner in our Center (visit 1);
• Have their physical activity and sleep assessed over 14 days with a wrist-work activity monitor;
• Have a saliva sample collected (visit 2), and
• Have body measurements taken (visits 2 and 3).

Mothers will be asked to complete questionnaires throughout the study. Participants will be compensated for their time.

Gastrointestinal motility disorders (GMD) and disorders of gut brain interactions (DGBI) include a wide spectrum of disease conditions, and it's relatively common in the general population. GMDs and DGBIs may be caused by impaired movement of muscles in the digestive system, impaired or oversensitive nerve signaling between the gut and brain, bacterial overgrowth, intolerance to certain foods, altered anatomy, or more. The purpose of this study is to collect and store data and samples, such as blood and saliva, for future research about GMD and DGBI. The study plans to enroll up to 5,000 participants, including patients with or without GMD and DGBI.

The study aims to understand which genes cause IBD and expand on what is known about how IBD affects those with African ancestry.

Patients are being recruited within the first two years of diagnosis at their scheduled infusion visits.

Participation in the study will last up to five years and includes an annual collection of blood, stool, and biopsy samples, and a one-time saliva sample at the first visit.

All study visits will align with clinically indicated visits already scheduled, and biopsy collection will only occur at scopes that are part of the patient's clinical care.

This study is being done in collaboration with hospitals around the country, and is headed by Emory University in Atlanta, Georgia. Participants will be compensated for their time and effort, upon completion of each visit.

The purpose of this study is to help understand how well new IBD medications work, obtain safety information, and understand patient's quality of life while on the medications.